Search
SV Health Investors Managing Partner Kate Bingham shares the firm's investment philosophy and gives her take on the current state of life sciences in the United Kingdom and beyond
Kate Bingham describes the type of investments SV makes, which was in the news this week for being the founding investor of the...
Jun 20
BIO International 2025: Oppenheimer's Head of Healthcare Investment Banking, Michael Margolis, discusses biotech sentiment, M&A, and what it is like to raise money today
He describes how sentiment and the M&A environment have been improving, as well as some areas of the financing market. However, he...
Jun 17
BIO International 2025: Stifel's Tim Opler comments on improvements in sentiment he is seeing for the biotech sector, and his take on hot button issues
He explains how M&A and fundraising have been improving, and he describes what types of companies have been most appealing to investors....
Jun 16
BIO International 2025: An intro to the BIO International Convention, and stopping by the Korea Pavilion
From the floor of the 2025 BIO International Convention in Boston, Brad Loncar describes what this four-day conference is all about, and...
Jun 16
Microsoft's Chief Scientific Officer for Health and Life Sciences shares his take on how AI is changing healthcare today and what is possible in the future
Matthew Lungren describes his belief how AI will "save time before it saves lives," and discusses how the clinical workforce is getting...
Jun 13
Klein Hersh at #ASCO25
Lonnie Brantz, Zach Spitz, and Jeffrey Azarva stopped by to discuss oncology trends, the evolving talent landscape, and the importance of...
Jun 2
Deerfield Management Managing Partner James Flynn discusses a new $600M venture fund the firm has raised and describes how it will be invested, including into AI companies
He describes raising the fund, and his take on the current challenging environment in healthcare. Plus, his thoughts on AI specifically,...
Jun 2
Piper Sandler Senior Analyst David Amsellem reacts to today's Teva Innovation & Strategy Day and shares his take on the company's pipeline
He gives his thoughts on the competitiveness of Teva's TL1A, and highlights other pipeline programs that biotech investors might look at....
May 29
Previewing top breast cancer and antibody-drug conjugate presentations to watch at this week's ASCO Annual Meeting with Dana-Farber's Paolo Tarantino
He describes key presentations for Enhertu, TRODELVY, immunotherapy medicines, and a couple key biomarkers to watch.
May 28
RBC Global Healthcare Conference: Desk Strategist Chris McCarthy shares how institutional investors have been affected by policy and macro factors, and how they have been positioning around catalysts
He describes how policy, macro, and events have been affecting trading in biotech stocks lately. Plus, his thoughts on the pull back of...
May 21
RBC Global Healthcare Conference: Senior Biotech Analyst Luca Issi shares his thoughts on the current state of gene and cell therapy
He shares his overall thoughts on the biotech market, and discusses gene therapies, RNA editing, and cell therapy. Luca Issi RBC 2025
May 21
RBC Global Healthcare Conference: RBC's Brian Abrahams shares his take on biotech and offers advice for companies on how to navigate these times of change
He describes some of the discussions he is having at the conference, discusses the difference between how large companies he covers are...
May 21
ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development
As published in NEJM today , UPenn's Kiran Musunuru describes how the team used base editing in a matter of months to treat an infant...
May 15
Gene therapies expert TJ Cradick previews what to watch for at the 2025 ASGCT Annual Meeting in New Orleans
He discusses the clinical programs, delivery vehicle advances, and safety improvements to watch for this year as the field of cell and...
May 13
Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera
He describes the current environment for life sciences in Europe and how far it has come over the last ten years. Plus, his thoughts on...
May 9
BioVenture VoiCes Episode 18: Playground Global's Jory Bell
Jory Bell shares the details of his expansive educational background and early career, which included being a product designer at Apple...
May 4
At a reception on the eve of Swiss Biotech Day, Swiss Biotech Association CEO Michael Altorfer introduces us to the conference and shares his thoughts on the state of biotech and global collaboration
He describes the goals of Swiss Biotech Day, explains how the Swiss biotech sector is funded more by private investment than perhaps...
May 4
Biotech investor Thilo Schroeder of Nextech Invest shares his take on biotech and discusses portfolio companies Revolution Medicines, Tubulis, and Circle Pharma
He describes the history of Nextech, including being an early investor in Blueprint Medicines and Peloton Therapeutics, and discusses the...
May 2
As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact
CSO John Connolly describes how recent new hires and a willingness to lead will expand PICI's already broad reach in cancer research...
Apr 16
Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why
Dr. Schlessinger describes how the new center is meant to speed up drug discovery work and enable Mount Sinai researchers to develop...
Apr 10
.png){kind=logo}
